HAVN Life Sciences Inc. (C:HAVN*CA)
Business Focus: Biotechnology & Medical Research (NEC)
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| Company Contact | |
| Address: | 605 - 130 Brew Street PORT MOODY BC V3H 0E3 |
| Tel: | N/A |
| Website: | https://havnlife.com |
| IR: | See website |
| Key People | ||
| Tim Moore Director and Chief Executive Officer | Ricky Brar Vice Chairman of the Board, Independent Director | Gordon Clissold Chief Financial Officer |
| Jenna Pozar Chief Operating Officer | Gary Joseph Leong Chief Scientific Officer | Ivan Casselman Chief Psychedelics Office | Alexzander Samuelsson Chief Research Officer |
| Business Overview |
| HAVN Life Sciences Inc. is a Canada-based biotechnology company. The Company is engaged in the scientific research and development of psychopharmacological and natural health care products. It is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing mental health treatments to support brain health and enhance the capabilities of the mind. The Company has two business divisions: HAVN Labs and HAVN Retail. The HAVN Labs division is engaged in the development of research protocols to cover the production of Psilocybe spp. Through its research division, HAVN Labs, it has developed an end-to-end supply chain of GMP naturally derived psychedelic compounds for research. The HAVN Retail division formulates and sells natural health products (NHPs) using compounds. It offers a full range of mushroom and plant extracts that help boost immune function, reduce inflammation and support a healthy lifestyle. |
| Financial Overview |
| For the nine months ended 31 January 2023, HAVN Life Sciences Inc revenues increased from C$60K to C$371K. Net loss decreased 61% to C$4.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Share-based payments decrease of 86% to C$222K (expense), Investor relations and marketing decrease of 79% to C$282K (expense). |
| Employees: | 6 as of Apr 30, 2021 |
| Reporting Currency: | Canadian Dollars |
| Enterprise value: | $0.19M as of Jan 31, 2023 |
| Annual revenue (TTM): | $0.59M as of Jan 31, 2023 |
| EBITDA (TTM): | -$4.65M as of Jan 31, 2023 |
| Net annual income (TTM): | -$15.71M as of Jan 31, 2023 |
| Free cash flow (TTM): | -$2.61M as of Jan 31, 2023 |
| Net Debt Last Fiscal Year: | $0.01M as of Jan 31, 2023 |
| Shares outstanding: | 28,646,020 as of Nov 3, 2023 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.